Arcturus Therapeutics Holdings Inc. (ARCT) Form 8-K — Aug 6, 2026
Arcturus Therapeutics reported Q2 2026 revenue of $3.0 million, down sharply from $28.3 million a year earlier, as collaboration revenue from CSL Seqirus wound down ahead of the partnership's termination. Net loss widened to $23.8 million, or $0.84 per share, from $9.2 million, or $0.34 per share, in Q2 2025. Arcturus and CSL Seqirus concluded their sa-mRNA collaboration through a termination and settlement agreement that returns global rights to KOSTAIVE and the infectious disease vaccine portfolio (seasonal and pandemic influenza, RSV, EBV) to Arcturus, subject to existing Meiji Seika Pharma arrangements in Japan for the 2026-2027 season.
Key figures
- Revenue
- 2959000
- Revenue Yoy
- -89.5% (vs. $28.3 million in Q2 2025)
- Total Assets
- 224310000
- Cash Position
- 191483000
- Shares Outstanding
- 28423000
- Cash runway
- over two and a half years through year end 2028
- Ga expense q2
- 10989000
- Rnd expense q2
- 17515000
- Cash dec 31 2025
- 230909000
- Patent portfolio
- over 500 patents and patent applications
- Revenue six months
- 5020000
- Prior year q2 revenue
- 28301000
- Arct032 phase3 decision timing
- Q4 2026
- Seqirus settlement cash payment
- 12000000
- Arct810 data and regulatory plan
- Q3 2026
- Seqirus released liabilities value
- 16000000
Price after filing
Close on the filing date to close N calendar days later (from $6.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.